Is YMI a buy? - Seeking Alpha

Quote & Headlines Market Currents StockTalk

Today 5d 1m 3m 1y 5y 10y

52wk high:

52wk low:

EPS:

PE:

Div Rate:

Yield:

Market Cap:

Volume:

485 people get YMI articles and Market Currents by email alert.

Get email alerts on YMI »

HEADLINES:

Gilead Sciences completes acquisition of YM BioSciences

PR Newswire (Feb 8, 2013)
YM BioSciences Reports Operational and Financial Results for the Second Quarter of Fiscal 2013

PR Newswire (Feb 7, 2013)
Predicting Biotech Stock Moves Based On Consensus Picks By Legendary Fund Managers
GuruFundPicks • Tue, Feb 5 • 3 Comments
YM BioSciences Announces Receipt of Final Court Order Approving the Plan of Arrangement with Gilead Sciences

PR Newswire (Feb 5, 2013)
YM BioSciences Shareholders Approve Plan of Arrangement with Gilead Sciences

PR Newswire (Jan 31, 2013)
Anything For A Buck: Jim Letourneau Looks To Canadian Biotech For Opportunity
Life Sciences Report • Fri, Jan 18 • 6 Comments
YM BioSciences Inc. Plan of Arrangement with Gilead Sciences, Inc. Endorsed by Leading Independent Proxy Advisors ISS and Glass Lewis

PR Newswire (Jan 18, 2013)
Canadian Biotech Isn't Dead; Following The Money To Undervalued Equities
Nouvelle Asset Management • Fri, Dec 28, 2012 • 1 Comment
Biotech Portfolio Update: 2012 Summary And 2013 Outlook
Ohad Hammer • Mon, Dec 24, 2012 • 11 Comments
YM BioSciences Announces Record Date for Previously Announced Plan of Arrangement

PR Newswire (Dec 21, 2012)
Oncolytics Biotech: What Is All The Excitement About?
C.R. Jackson • Tue, Dec 18, 2012 • 2 Comments
A Not-So-Bad Acquisition By Gilead
Henry Kawabe • Fri, Dec 14, 2012
Today's Market News To Trade On: 5 Stocks Moving On News
Matthew Smith • Thu, Dec 13, 2012 • 9 Comments
YM BioSciences's Strange Journey Comes To A Strange Conclusion
Stephen Simpson • Wed, Dec 12, 2012 • 5 Comments
Stock Watch Wednesday, 12 December
VFC's Stock House • Wed, Dec 12, 2012
Gilead Sciences to Acquire YM Biosciences

PR Newswire (Dec 12, 2012)
YM BioSciences Reports Phase I/II Data for JAK Inhibitor CYT387 in Myelofibrosis at ASH 2012

PR Newswire (Dec 9, 2012)
YM BioSciences Reports Divestiture of Nimotuzumab Assets by CIMYM

PR Newswire (Dec 3, 2012)
YM BioSciences Announces Election of Dr. Kapil Dhingra to its Board of Directors

PR Newswire (Nov 20, 2012)
ASH 2012 Preview: Top Picks For Upcoming Blood Cancer Meeting
Ohad Hammer • Mon, Nov 12, 2012 • 2 Comments

To learn more about Seeking Alpha Pro, click here.

YM BioSciences's Strange Journey Comes To A Strange Conclusion
Stephen Simpson • Wed, Dec 12, 2012 • 5 Comments
The Wait Goes On At YM Biosciences
Stephen Simpson • Tue, Sep 4, 2012 • 14 Comments
YM Biosciences: The Next Way To Get Long Myelofibrosis
LifeSci Advisors • Thu, May 3, 2012 • 5 Comments
YM BiOSciences' Cheap Valuation Doesn't Make Sense
Stephen Simpson • Thu, Mar 22, 2012 • 28 Comments
YM's Positive Results Have Incyte Investors Worried
EP Vantage • Thu, Dec 15, 2011 • 7 Comments
YM BioSciences' Upcoming CYT387 Catalyst May Be One To Watch
M. E. Garza • Tue, Nov 1, 2011 • 7 Comments
YM Biosciences' Business Model May Discourage Long-Term Investors
James Stocklasar Thomas Jr. • Mon, Mar 28, 2011 • 14 Comments
YM BioSciences Is Loaded with Potential
VFC's Stock House • Thu, Aug 27, 2009 • 3 Comments
YM BioSciences: Trading Below Cash with Multiple Catalysts
Mike Havrilla • Sun, Aug 9, 2009 • 3 Comments
BBM Looks for Bargain in YM Biosciences Acquisition Proposal
Eben Tessari • Sat, Nov 15, 2008 • 1 Comment
YM Biosciences' Trials Are Worth Watching
Michael Shulman • Thu, Feb 21, 2008 • 1 Comment
YM BioSciences: YMI Trading Below Cash?
Mike Havrilla • Fri, Dec 14, 2007
Versant: YM Biosciences Now a 'Speculative Buy'
FP Trading Desk • Tue, Apr 10, 2007

Predicting Biotech Stock Moves Based On Consensus Picks By Legendary Fund Managers
GuruFundPicks • Tue, Feb 5 • 3 Comments
Anything For A Buck: Jim Letourneau Looks To Canadian Biotech For Opportunity
Life Sciences Report • Fri, Jan 18 • 6 Comments
Canadian Biotech Isn't Dead; Following The Money To Undervalued Equities
Nouvelle Asset Management • Fri, Dec 28, 2012 • 1 Comment
Biotech Portfolio Update: 2012 Summary And 2013 Outlook
Ohad Hammer • Mon, Dec 24, 2012 • 11 Comments
Oncolytics Biotech: What Is All The Excitement About?
C.R. Jackson • Tue, Dec 18, 2012 • 2 Comments
A Not-So-Bad Acquisition By Gilead
Henry Kawabe • Fri, Dec 14, 2012
Today's Market News To Trade On: 5 Stocks Moving On News
Matthew Smith • Thu, Dec 13, 2012 • 9 Comments
Stock Watch Wednesday, 12 December
VFC's Stock House • Wed, Dec 12, 2012
ASH 2012 Preview: Top Picks For Upcoming Blood Cancer Meeting
Ohad Hammer • Mon, Nov 12, 2012 • 2 Comments
AcelRx Pharmaceuticals: Next Generation Of Pain Management Technologies
LifeSci Advisors • Mon, Jul 16, 2012 • 7 Comments
10 Rallying Stocks Under $5 Being Bought Up By Hedge Funds
Kapitall • Sun, Jun 17, 2012 • 1 Comment
Healthcare Stocks On The Move In A Difficult Market
StockPandit • Wed, Jun 6, 2012 • 6 Comments
These Biotechs May Break Out While Vivus And Arena Battle It Out
James Stocklasar Thomas Jr. • Mon, May 28, 2012 • 1 Comment
Gilead's Hematology Pipeline: Transformative And Under-Appreciated
Ohad Hammer • Sun, May 6, 2012 • 3 Comments
Top Micro Cap Biotech Stocks Being Accumulated By Legendary Fund Managers
GuruFundPicks • Tue, Apr 17, 2012 • 12 Comments
16 Biotech Stocks Sold Off By Hedge Funds
Kapitall • Mon, Apr 2, 2012 • 1 Comment
7 Bullish Reasons To Buy Zalicus Right Now
James Stocklasar Thomas Jr. • Mon, Mar 19, 2012 • 29 Comments
Top High Conviction Picks Of Biotech-Focused Baker Bros. $3.0 Billion 13-F Portfolio
GuruFundPicks • Wed, Mar 7, 2012 • 2 Comments
Jakafi Launch: Survey Reveals Upside To Stock
LifeSci Advisors • Tue, Jan 24, 2012 • 1 Comment
5 Winners Of American Society Of Hematology 2011
Ohad Hammer • Mon, Dec 19, 2011 • 6 Comments

There are no Transcripts on YMI.

Gilead Sciences completes acquisition of YM BioSciences

PR Newswire (Feb 8, 2013)
YM BioSciences Reports Operational and Financial Results for the Second Quarter of Fiscal 2013

PR Newswire (Feb 7, 2013)
YM BioSciences Announces Receipt of Final Court Order Approving the Plan of Arrangement with Gilead Sciences

PR Newswire (Feb 5, 2013)
YM BioSciences Shareholders Approve Plan of Arrangement with Gilead Sciences

PR Newswire (Jan 31, 2013)
YM BioSciences Inc. Plan of Arrangement with Gilead Sciences, Inc. Endorsed by Leading Independent Proxy Advisors ISS and Glass Lewis

PR Newswire (Jan 18, 2013)
YM BioSciences Announces Record Date for Previously Announced Plan of Arrangement

PR Newswire (Dec 21, 2012)
Gilead Sciences to Acquire YM Biosciences

PR Newswire (Dec 12, 2012)
YM BioSciences Reports Phase I/II Data for JAK Inhibitor CYT387 in Myelofibrosis at ASH 2012

PR Newswire (Dec 9, 2012)
YM BioSciences Reports Divestiture of Nimotuzumab Assets by CIMYM

PR Newswire (Dec 3, 2012)
YM BioSciences Announces Election of Dr. Kapil Dhingra to its Board of Directors

PR Newswire (Nov 20, 2012)
YM BioSciences Reports Operational and Financial Results for the First Quarter of Fiscal 2013

PR Newswire (Nov 9, 2012)
YM BioSciences JAK Inhibitor CYT387 Produces Meaningful Reductions of Splenomegaly and Durable Transfusion Independence Responses

PR Newswire (Nov 5, 2012)
YM BioSciences Reports CYT387 Phase I/II Results Selected for Oral Presentation at ASH2012 Conference

PR Newswire (Oct 11, 2012)
YM BioSciences Reports Fiscal 2012 Operational and Financial Results

PR Newswire (Sep 21, 2012)
YM BioSciences Reports Operational and Financial Results for the Third Quarter of Fiscal 2012

PR Newswire (May 11, 2012)
YM BioSciences Reports Updated Phase I/II Data for its JAK1/JAK2 Inhibitor CYT387 at ASH 2011

PR Newswire (Dec 12, 2011)
Rivals Gain on Pfizer Drug Trial News

at CNBC.com (Apr 21, 2011)
Canada’s limited health-care opportunities

at MarketWatch.com (Oct 19, 2010)

YMI vs. ETF Alternatives

Company Description

Currently, there's no company description for YMI.

Sector: Healthcare

Industry: Drug Manufacturers - Other

Country: Canada

All
| Earnings
| Dividends
| M&A
| On the move

Thursday, February 7, 9:26 AM YM BioSciences (YMI): FQ2 EPS of -$0.07 misses by $0.01. Revenue of $3.86M beats by $2.3M. (PR) Comment! [Earnings, Breaking News, Healthcare]
Friday, January 18, 3:43 PM YM BioSciences (YMI) says its buyout by a wholly owned subsidiary of Gilead Sciences (GILD +0.8%) has been endorsed by proxy advisory firms Institutional Investor Services and Glass, Lewis & Co. ISI says the all-cash deal offers a satisfactory premium, while Glass Lewis also notes that the YMI board of directors conducted a reasonable review of strategic alternatives available to the company prior to entering into the proposed agreement. Comment! [Healthcare, M&A]
Wednesday, December 12, 2012, 12:45 PM Midday top 10 gainers: YMI +77%. DSTI +73%. TELK +25%. LDK +21%. JKS +23%. JASO +21%. TSL +20%. YGE +19%. CBMX +14%. SOL +17%.
Midday top 10 Losers: RSOL -14%. CENT -13%. ACUR -11%. TAS -11%. CATO -10%. CRWS -9%. AVD -9%. CRL -8%. AXK -8%. LTBR -8%. Comment! [On the Move]
Wednesday, December 12, 2012, 9:46 AM Gilead Sciences (GILD +0.4%) agrees to acquire YM BioSciences (YMI) for $510M, with the $2.95/share offer representing an 81% premium to the latter's close of $1.63 yesterday. With the deal, Gilead will gain access to YM's blood and immune cell disorder drugs. Its lead drug candidate is CYT387 for treating myelofibrosis, a progressive, chronic bone marrow disease. YM shares sky 78%. (PR) Comment! [Healthcare, On the Move, M&A]
Wednesday, December 12, 2012, 9:10 AM Premarket gainers: YMI +79%. DSTI +15%. SCMP +11%. ACAD +9%. BGMD +10%.
Losers: RSOL -16%. CIE -11%. MCP -6%. Comment! [On the Move]
Wednesday, February 22, 2012, 10:28 AM YM Biosciences (YMI +6.3%) gets a boost from postitive comments out of Wells Fargo this morning, saying that recent weakness has created a buying a opportunity in the stock. Wells believes investors are failing to recognize the potential of the company's lead drug as both a treatment for myelofibrosis as well as other applications. Comment! [Healthcare, On the Move, Quick Ideas]
Tuesday, December 13, 2011, 1:32 PM Shares of YM Biosciences (YMI +16.1%) fall back to earth a bit after surging over 20% in AH and premarket trading on positive results on testing of its CYT387 drug. Rodman & Renshaw's Reni Benjamin says the big takeaway from the data is that it meets the threshold of attracting interest from other companies looking to partner. Comment! [On the Move, Healthcare, Quick Ideas]
Tuesday, December 13, 2011, 9:05 AM Premarket gainers: SYNO +51%. YMI +23%. URBN +12%. AMR +12%. MBI +9%. MS 9+5 ARNA +5%. AINV +4%. DMND +3%. CLWR +3%. AEZS +3%. DRYS +3%.
Losers: IVN -15%. BBY -8%. PSE -5%. IRE -3%. Comment! [On the Move]
Monday, December 12, 2011, 5:27 PM YM BioSciences (YMI) surges 21.9% AH after reporting positive results for the Phase I/II study of its CYT387 drug for treating myleofibrosis, both with regards to efficacy and safety. The company hopes to start "pivotal trials" for the drug in mid-2012. Comment! [Healthcare, On the Move]
Thursday, July 7, 2011, 9:05 AM Premarket gainers: APAC +56%. MCZ +14%. OCZ +9%. RENN +8%. PMI +7%. TGT +6%. REDF +5%. DANG +5%. KSS +5%. MOBI +5%. STX +4%. BPAX +4%. GPL +4%. LTD +4%. ASML +4%. YOKU +3%. M +3%. STD +3%. SODA +3%. SINA +3%. NOK +3%. RDN +3%.
Losers: AFFX -16%. LL -16%. FST -7%. YMI -6%. JCP -4%. AIB -3%. Comment! [On the Move]
Tuesday, December 14, 2010, 9:00 AM Premarket gainers: GXDX +17%. AMGN +4%. BP +4%.
Losers: LCI -13%. BBY -13%. LPH -12%. ICO -11%. LXRX -10%. YMI -8%. AHT -6%. OXPS -5%. VECO -5%. REE -5%. WPZ -4%. Comment!
Monday, April 19, 2010, 9:00 AM Premarket gainers: CRN +35%. YMI +9%. CTIC +5%. IMMU +4%. SQNM +4%.
Losers: RNN -13%. TSFG -7%. SPF -7%. PALM -6%. FRE -5%. FNM -5%. Comment!
Thursday, September 17, 2009, 9:00 AM Premarket gainers: AMR +20%. YMI +19%. BBI +8%. PIR +7%. RZ +5%. DFS +4%. LCC +4%. MGM +4%. CVM +4%.
Losers: SNV -7%. EXK -6%. AIB -4%. Comment!

Asif Suria
New Post: Merger Arbitrage Mondays http://bit.ly/Xxoa0B $IN $HLYS $TNS $SOMX $YMI
12/17/12
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

The Scientist
$ONCY potential is huge. Reolysin can also be used for many other cancer types. Following: $CYCC $CYTK $ONCY $SNTA $SRPT $YMI
12/13/12
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

The Scientist
Glad to see $YMI get the respect it deserved for CYT387. $GILD is one sharp biotech firm. HIV/HepC and now oncology.
12/13/12
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

VFC's Stock House
Stock Watch Thursday - $BBRY, $AMRN, $GILD, $YMI, $TROV, $ONVO, $PFE, $UTHR - http://bit.ly/cAHZ42
12/13/12
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

Asif Suria
Gilead Sciences to Acquire YM Biosciences for $510 million $YMI $GILD http://bit.ly/XcvFtV
12/12/12
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

VFC's Stock House
Stock Watch Wednesday - $AMRN, $MCD, $PBTH, $YUM, $TROV, $YMI, $GILD, $ONTY, $DNDN, $TEVA vfcsstockhouse.com
12/12/12
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

The Scientist
YMI CYT387 superior to INCY ruxolitinib. Ruxo should NOT have been approved by FDA. Look @ Youtube video Dr. Pardanani on ruxo. Ruxo is junk
12/10/11
Reply (5)

• !Report Abuse
View all 5 replies
jsandresen1: Niether drugs are cures. The most exciting news could be Cornerstone's drug Zyflo, read this story. http://www.mpnforum.com
3/15/12
• !Report Abuse
TruffelPig: What is this for a sharp comment? Zyflo isn't a cure either and in addition has nothing to do with an anti cancer drug.
3/15/12
• !Report Abuse
Add a reply...

140 characters

Bikas Sharma
YMI's drug addresses anemia better than INCY which is considered the most important variable for survival in PMF.http://bit.ly/j6rm2M
6/8/11
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

Bikas Sharma
YMI being down doesn't bother me the same way as INCY being up.In 2 months we will know where we stand.I recommend buying YMI at all dips.
6/7/11
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

Bikas Sharma
AH $3.58. Looks like YMI is getting ready for the big league. Come ASCO we will know.Watch out INCY.
5/25/11
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

LATEST REPLIES

The Scientist
YMI CYT387 superior to INCY ruxolitinib. Ruxo should NOT have been approved by FDA. Look @ Youtube video Dr. Pardanani on ruxo. Ruxo is junk
12/10/11
Reply (5)

• !Report Abuse
View all 5 replies
jsandresen1: Niether drugs are cures. The most exciting news could be Cornerstone's drug Zyflo, read this story. http://www.mpnforum.com
3/15/12
• !Report Abuse
TruffelPig: What is this for a sharp comment? Zyflo isn't a cure either and in addition has nothing to do with an anti cancer drug.
3/15/12
• !Report Abuse
Add a reply...

140 characters

YMI YM BioSciences Inc.

YMI

YM BioSciences Inc.